Log in to post a reply
Apr 28, 2019 01:34PM
Apr 28, 2019 01:37PM
If you read the Daily Mail article that Chicagoan posted at the top of this thread, you'll see that he took this drug (as a supplement) while he was on a clinical trial. Initially he didn't tell his doctor he was doing it, then eventually fessed up, after it was clear he was having an exceptional response and they decided to investigate why he responded so well. Because he had late-stage lung cancer, we can assume that his trial included at least one immunotherapy drug, maybe even an immuno combo.
It's as if doxil or navelbine had not yet been recognized to have anti-cancer properties, and you realized that you could take them on your own without a prescription, or having to worry about any serious side effects. But would you really want to use it that way? Luce says mebendazole is offered in a clinical trial at UCSD in combination with immunotherapy- suppose they find out that their protocol works great? if you take it now, you might not be eligible to get into a trial combining it with immunotherapy These compounds look like potentially powerful drugs, I wouldn't really be comfortable munching them like a supplement. I was surprised to find that some of the CDK9-type inhibitors can also be found off-prescription in the nutritional supplement stores, apparently bodybuilders have been using them for quite awhile.
UCSD is smart to offer mebendazole in a trial, because its off-patent and virtually none of their late-stage patients would have been exposed to the drug before. Plus, there are few side effects so it can be combined with immunotherapy, and what is known about the mechanism of action suggests the combo might work for a variety of cancers.
OTOH, this guy took them as a supplement, during his trial, and he lucked out. People do this kind of thing all the time. I doubt vitamins or CBD oil have any magical role in the combination, but who knows? If they work great, hopefully we'll hear about the trial from the UCSD folks sometime soon..
10/2003, IDC, Stage IIB, ER+/PR+, HER2-
7/2015, Stage IV, metastasized to bone, ER+/PR-, HER2-